Page 5 - Medicines Stock Down News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Medicines stock down. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Medicines Stock Down Today - Breaking & Trending Today

Blueprint Medicines (NASDAQ:BPMC) Releases Earnings Results, Beats Estimates By $0.39 EPS

Blueprint Medicines (NASDAQ:BPMC) Releases Earnings Results, Beats Estimates By $0.39 EPS
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United States , Percyh Carter , Wells Fargo Company , Steward Partners Investment Advisory , Blueprint Medicines Corporation , Needham Company , Jpmorgan Chase Co , Blueprint Medicines Company Profile , Squarepoint Ops , Securities Exchange Commission , Geode Capital Management , Blueprint Medicines , Get Free Report , Medicines Stock Down , Wells Fargo , Exchange Commission , Bay Capital Management , Partners Investment Advisory , Capital Management , Medicines Corporation , Blueprint Medicines Daily ,

Revolution Medicines (NASDAQ:RVMD) Given New $40.00 Price Target at Oppenheimer

Revolution Medicines (NASDAQ:RVMD – Free Report) had its price objective upped by Oppenheimer from $35.00 to $40.00 in a research note issued to investors on Wednesday, Marketbeat.com reports. Oppenheimer currently has an outperform rating on the stock. Several other equities analysts also recently issued reports on RVMD. HC Wainwright reissued a buy rating and set […] ....

Hong Kong , Jack Anders , Stephen Michael Kelsey , Tower Research Capital , Needham Company , Revolution Medicines Inc , Hong Kong Ltd , Jpmorgan Chase Co , Belpointe Asset Management , Allspring Global Investments Holdings , Revolution Medicines , Free Report , Moderate Buy , Medicines Stock Down , Get Free Report , Asset Management , Kong Ltd , Global Investments Holdings , Research Capital , Revolution Medicines Daily ,

StockNews.com Lowers Blueprint Medicines (NASDAQ:BPMC) to Sell

StockNews.com lowered shares of Blueprint Medicines (NASDAQ:BPMC – Get Rating) from a hold rating to a sell rating in a research report sent to investors on Friday. Several other research analysts have also recently issued reports on BPMC. HC Wainwright increased their price objective on Blueprint Medicines from $75.00 to $85.00 in a research report […] ....

United States , Percyh Carter , Stifel Nicolaus , Squarepoint Ops , Blueprint Medicines Corporation , Jpmorgan Chase Co , Capital Impact Advisors , Blueprint Medicines Company Profile , Macquarie Group Ltd , Blueprint Medicines , Get Rating , Medicines Stock Down , Impact Advisors , Bay Capital Management , Medicines Corporation , Blueprint Medicines Daily ,

Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com

SVB Securities lowered shares of Blueprint Medicines (NASDAQ:BPMC – Get Rating) from a market perform rating to an underperform rating in a research report report published on Monday morning, The Fly reports. SVB Securities currently has $43.00 price objective on the biotechnology company’s stock, down from their previous price objective of $48.00. Other analysts have […] ....

United Kingdom , Chris Varma , Raymond James , Percyh Carter , Brian Druker , Nicholasb Lydon , Needham Company , Associates Corp , Securities Exchange Commission , Blueprint Medicines Corp , Bessemer Group Inc , Lazard Asset Management , Blueprint Medicines , Get Rating , Medicines Stock Down , Exchange Commission , Asset Management , Forest Capital Management , Quantbot Technologies , Alexis Borisy , Blueprint Medicines Daily ,

Blueprint Medicines (NASDAQ:BPMC) Shares Down 5.9% After Insider Selling

Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) shares traded down 5.9% on Thursday following insider selling activity. The stock traded as low as $56.44 and last traded at $56.48. 317,027 shares changed hands during mid-day trading, a decline of 45% from the average session volume of 581,232 shares. The stock had previously closed at $60.03. […] ....

United Kingdom General , United Kingdom , Raymond James , Percyh Carter , Chris Varma , Nicholasb Lydon , Brian Druker , Blueprint Medicines Company Profile , Blackrock Inc , Marshall Wace , Norges Bank , Blueprint Medicines Co , Pricet Rowe Associates Inc , Blueprint Medicines Corp , Blueprint Medicines , Get Rating , Medicines Stock Down , Street Corp , Alexis Borisy , Blueprint Medicines Daily , Nasdaq Bpmc ,